POS0215 DIRECT AND CONDITIONAL EFFECTS OF EPICARDIAL ADIPOSE TISSUE VOLUME ON CORONARY PLAQUE PROGRESSION IN RHEUMATOID ARTHRITIS
Authors: G. Karpouzas, S. Ormseth, E. Hernandez, M. Budoff
Journal: Annals of the Rheumatic Diseases (2021)

Background: Epicardial adipose tissue volume (EATv) predicts coronary atherosclerosis presence, progression and cardiovascular event risk in general patients 1,2 . Our group recently reported that EATv associated with greater subclinical coronary plaque burden, non-calcified plaque presence and vulnerable plaque characteristics in patients with rheumatoid arthritis (RA). The relationship was stronger in RA patients with lower disease duration, no traditional cardiac risk factors, and who were not obese. Objectives: To evaluate the predictive value of EATv on long-term coronary atherosclerosis development, and moderators of the association between EATv and plaque formation. Methods: This single-center observational cohort study included 100 patients without symptoms or diagnosis of cardiovascular disease who underwent computed tomography angiography for evaluation of EATv and coronary atherosclerosis at baseline and repeat assessments 6.9±0.3 years later to evaluate plaque progression. New plaque formation in segments without plaque at baseline was the main outcome. Robust multivariable logistic regression evaluated the effect of high versus low EATv (based on median) on likelihood of new plaque formation, accounting for clustering of segments within patients. Potential moderator effects of prespecified predictors were also assessed. Results: High EATv (&gt;107 cm 3 ) predicted new plaque formation in segments without baseline plaque (OR 2.77 [95% CI 1.43-5.37], p= 0.003); however, significance was lost in the multivariable model. Importantly, high EATv associated with formation of higher-risk non- and partially calcified plaque after adjusting for Framingham D’Agostino risk score, obesity, segment location, time-averaged CRP, duration of bDMARD and statin treatment and cumulative prednisone dose (adjusted OR 2.57 [95% CI 1.02-6.48], p= 0.045). RA duration (&lt;10 versus &gt;10 years), cardiac risk factor burden (≤1 versus &gt;1), presence of mixed/calcified plaque in other coronary segments at baseline, and statin exposure (≤1 versus &gt;1 year, based on median) moderated the effect of EATv on all new plaque formation (all p for interaction ≤ 0.021). Specifically, high EATv predicted new plaque formation in patients with RA duration &lt;10 years (adjusted OR 5.75 [95% CI 1.77-18.67]), those with ≤1 cardiac risk factors (adjusted OR 3.40 [95% CI 1.46-7.90]), those without calcification at baseline (adjusted OR 2.65 [95% CI 1.11-6.31]) and those with statin treatment &lt;1 year (adjusted OR 3.33 [95% CI 1.13-9.77]). This was not the case for patients with RA &gt;10 years, ≥ 2 cardiac risk factors, calcification at baseline and statin treatment &gt;1 year (figure 1). Conclusion: High baseline EATv independently predicted future higher-risk non-calcified and mixed coronary plaque in RA. Moreover, it conditionally promoted new plaque formation overall in patients with earlier disease, low cardiac risk factor burden, who had little or no atherosclerosis at baseline and who had limited exposure to statin therapy. These findings indicate the need for a larger prospective evaluation of the role of EATv as a biomarker of coronary atherosclerosis development in RA. References: [1]Hwang I-C et al. J Atheroscler Thromb 2017;24:262–74. 2. Ding J et al. Am J Clin Nutr 2009;90:499–504. Figure 1. Moderators of influence of EATv on new coronary plaque formation Disclosure of Interests: George Karpouzas Speakers bureau: Sanofi/ Genzyme/ Regeneron, Consultant of: Sanofi/ Genzyme/ Regeneron, Grant/research support from: Pfizer, Sarah Ormseth: None declared, Elizabeth Hernandez: None declared, Matthew Budoff Consultant of: Pfizer